Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2026-05-07 @ 7:25 PM
Study NCT ID:
NCT02957968
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-28
First Post:
2016-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Sponsor:
Virginia Commonwealth University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Adenocarcinoma | View |
| None | Estrogen Receptor- Negative Breast Cancer | View |
| None | Estrogen Receptor-positive Breast Cancer | View |
| None | HER2/Neu Negative | View |
| None | Invasive Breast Carcinoma | View |
| None | Progesterone Receptor Negative | View |
| None | Progesterone Receptor Positive Tumor | View |
| None | Stage II Breast Cancer | View |
| None | Stage IIA Breast Cancer | View |
| None | Stage IIB Breast Cancer | View |
| None | Stage IIIA Breast Cancer | View |
| None | Stage IIIB Breast Cancer | View |
| None | Triple-negative Breast Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast Cancer | View |